A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Losartan
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Arbor Pharmaceuticals
- 25 Jan 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, according to ClinicalTrials.gov record.
- 25 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2018, according to ClinicalTrials.gov record.
- 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.